Vicente Rubio

Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome

Miguel Á. Sanz, Pau Montesinos, Chelo Rayón et al. · Blood · 2010 · 336 citations · Full text

Medicine, Oncology, Pharmacology +16

BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors

MD Caballero, Vicente Rubio, J. Rifón et al. · Bone Marrow Transplantation · 1997 · 153 citations

Medicine, Oncology, Chemotherapy +14

Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens

Pau Montesinos, Chelo Rayón, Edo Vellenga et al. · Blood · 2010 · 143 citations · Full text

Medicine, Hematology, Oncology +14

Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention

Jordi Esteve, Lourdes Escoda, Vicente Rubio et al. · Leukemia · 2007 · 120 citations

Medicine, Oncology, Pharmacology +16

Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis

Pau Montesinos, J Díaz-Mediavilla, Guillermo Debén et al. · Haematologica · 2009 · 100 citations · Full text

Medicine, Oncology, Pharmacotherapy +13